Mark Sheptoff Financial Planning’s Progenics Pharmaceuticals Inc PGNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-10
| Closed | – | – | 379 |
|
|
2020
Q1 | $0 | Hold |
10
| – | – | ﹤0.01% | 395 |
|
|
2019
Q4 | $0 | Hold |
10
| – | – | ﹤0.01% | 388 |
|
|
2019
Q3 | $0 | Hold |
10
| – | – | ﹤0.01% | 404 |
|
|
2019
Q2 | $0 | Hold |
10
| – | – | ﹤0.01% | 374 |
|
|
2019
Q1 | $0 | Hold |
10
| – | – | ﹤0.01% | 374 |
|
|
2018
Q4 | $0 | Hold |
10
| – | – | ﹤0.01% | 376 |
|
|
2018
Q3 | $0 | Hold |
10
| – | – | ﹤0.01% | 389 |
|
|
2018
Q2 | $0 | Hold |
10
| – | – | ﹤0.01% | 397 |
|
|
2018
Q1 | $0 | Hold |
10
| – | – | ﹤0.01% | 404 |
|
|
2017
Q4 | $0 | Hold |
10
| – | – | ﹤0.01% | 391 |
|
|
2017
Q3 | $0 | Hold |
10
| – | – | ﹤0.01% | 396 |
|
|
2017
Q2 | $0 | Sell |
10
-1
| -9% | -$7 | ﹤0.01% | 381 |
|
|
2017
Q1 | $0 | Buy |
11
+1
| +10% | +$10 | ﹤0.01% | 376 |
|
|
2016
Q4 | $0 | Hold |
10
| – | – | ﹤0.01% | 378 |
|
|
2016
Q3 | $0 | Hold |
10
| – | – | ﹤0.01% | 380 |
|
|
2016
Q2 | $0 | Hold |
10
| – | – | ﹤0.01% | 381 |
|
|
2016
Q1 | $0 | Hold |
10
| – | – | ﹤0.01% | 408 |
|
|
2015
Q4 | $0 | Hold |
10
| – | – | ﹤0.01% | 437 |
|
|
2015
Q3 | $0 | Hold |
10
| – | – | ﹤0.01% | 458 |
|
|
2015
Q2 | $0 | Hold |
10
| – | – | ﹤0.01% | 409 |
|
|
2015
Q1 | $0 | Hold |
10
| – | – | ﹤0.01% | 349 |
|
|
2014
Q4 | $0 | Hold |
10
| – | – | ﹤0.01% | 347 |
|
|
2014
Q3 | $0 | Hold |
10
| – | – | ﹤0.01% | 356 |
|
|
2014
Q2 | $0 | Hold |
10
| – | – | ﹤0.01% | 368 |
|
|
2014
Q1 | $0 | Buy |
+10
| New | +$51 | ﹤0.01% | 362 |
|
Other funds holding PGNX
Mark Sheptoff Financial Planning's PGNX Position: Q2 2020 in Review
Mark Sheptoff Financial Planning sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 10 shares.
Mark Sheptoff Financial Planning first reported a position in PGNX in Q1 2014 and held it in 25 quarters. The position peaked at $0 in Q1 2020. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.
- Mark Sheptoff Financial Planning reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
- Mark Sheptoff Financial Planning sold 10 Progenics Pharmaceuticals Inc shares in Q2 2020.
- Mark Sheptoff Financial Planning first reported a position in Progenics Pharmaceuticals Inc in Q1 2014 and held it in 25 quarters.
- Mark Sheptoff Financial Planning's Progenics Pharmaceuticals Inc position peaked at $0 in Q1 2020.
- 3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.
Based on Mark Sheptoff Financial Planning's 13F filing for Q2 2020, filed 10 Aug 2020.